Brief: Summit Therapeutics Q2 Net Income USD -60.4 Million
06/08/2024 12:00
Aug 06 (Reuters) - Summit Therapeutics Q2 operating expenses USD 59.8 million. * Q2 EPS USD -0.09 * Q2 operating income USD -59.6 million
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering